| Objective:through the 60 cases of cervical cancer patients with autologous dendritic cells(dendritic cells,DC)-cytokine induced killer cells(cytokine induced killer,CIK)adoptive immunotherapy,analysis the treatment of clinical therapeutic effect.Methods:accept DC-CIK immunotherapy for guizhou province people's hospital of oncology from sep 2012 to May 2016 were 60 cases was diagnosed with cervical cancer patients with stage ?B and ?,the above patients after conventional radiation and chemotherapy treatment,but there are still a residual lesions.60 patients on day 1 collection,80-100 ml peripheral blood in the lab for autologous DCS-CIK cell culture,on the 10th day,11 days for DC-CIK cells back to lose(once a day,a total of 2 times),as a course of 4 weeks.All 60 patients underwent 2-6 courses of dc-cik therapy.The dc-cik intervention was used to compare clinical indicators of five aspects of patients before and after treatment.Includes:the patient's immune function changes,the quality of life improves,the tumor marker changes,the adverse reaction occurs,the tumor objective curative effect.The evaluation methods of the above five aspects are evaluated by the corresponding objective evaluation indexes.(1)the immune function test:to observe the two weeks before and after treatment for 2 weeks in patients with peripheral blood T lymphocyte subsets(CD3 + and CD3 + CD4 + and CD3 + CD8 + and CD3 + CD56 + T cells)the ratio of the change,and granular enzyme and the expression of perforin,B is used to evaluate the influence of the body's immune function;(2)quality of life:the use of KPS scoring and pain NRS evaluation for the quality of life before and after treatment;Comparison of the various indicators before and after dc-cik treatment;(3)tumor marker changes:the use of SCCA,CA125,and the tumor markers used for cervical cancer were evaluated against tumor curative effect.(4)the side effect:according to the generic drug toxicity reaction standards promulgated by the national cancer institute(NCI-CTC),divided into 0?? degree,DC-CIK anti-tumor immune therapy for safety evaluation.(5)tumor change:according to solid tumor RECIST evaluation standard,in patients before and 4 weeks after treatment,CT,MRI,or ultrasound evaluation of 60 cases of patients with cancer tumor diameter changes.Results:compared with before treatment,the number of lymphocyte subsets of patients such as CD3+,CD8+,CD56+ and CD3 + CD8 + and CD3 + CD56 + was obviously higher,the significant difference(P<0.05).The expression of particle B and perforin were significantly increased(P<0.05);The patients' KPS scores improved significantly(P<0.01),the pain score was significantly lower(P<0.05),and the quality of life improved.The tumor markers SCCA and CA125 were significantly reduced(P<0.05);There was no obvious adverse reaction(P<0.05);The clinical benefit rate could reach 80%.Conclusion:DC-CIK anti-tumor immune therapy can significantly improve the immune function in patients with cervical cancer,to improve the quality of life,is clinically high safety,less adverse reaction,DC-CIK anti-tumor immune therapy to cerical cancer can make patients get clinical benefit,to promote of tiny residual lesions in patients with clear and prevent tumor recurrence and metastasis has a certain significance.This study provides the basic data for the application of DC-CIK anti-tumor immune therapy,and has certain clinical guiding significance. |
PDF Full Text Request